Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Lymphoma × vistusertib × Clear all

Phase

Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasms 2 Recurrence 1 Prostatic Neoplasms 1 Muscle Invasive Bladder Cancer 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma 1 Glioblastoma 1 Disease 1 Breast Neoplasms 1 Advanced Solid Malignancies 1 Advanced Metastatic Breast Cancer 1 Advanced Cancer 1

Interventions

Rituximab 53 Cyclophosphamide 53 fludarabine 35 fludarabine phosphate 29 Filgrastim 25 Etoposide 20 Melphalan 19 Gemcitabine 17 Bendamustine Hydrochloride 17 Vincristine 15 Cytarabine 15 Peripheral Blood Stem Cell Transplantation 14 Bortezomib 14 pembrolizumab 13 aldesleukin 13 Prednisone 13 Doxorubicin 12 Sirolimus 11 Busulfan 11 obinutuzumab 10 Whole-Body Irradiation 10 Vorinostat 10 Lenalidomide 10 Dexamethasone 10 Tacrolimus 9 sargramostim 8 romidepsin 8 Radiotherapy 8 Paclitaxel 8 Nivolumab 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02780830 2016-09-15

INHIBITOR

AstraZeneca

Phase 1 Withdrawn

Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon ⚡